Evidence map›Paper›PMID 27707973›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2016

T394A Mutation at the μ Opioid Receptor Blocks Opioid Tolerance and Increases Vulnerability to Heroin Self-Administration in Mice.

Xiao-Fei Wang, Elisabeth Barbier, Yi-Ting Chiu, Yi He, Jia Zhan, Guo-Hua Bi, Hai-Ying Zhang, Bo Feng, Lee-Yuan Liu-Chen, Jia Bei Wang and 1 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. A suite of engineered mice for interrogating psychedelic drug actions.bioRxiv : the preprint server for biology · 2023
    Article
  5. A highly DNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Article
  6. Review
  7. Substance abuse and neurotransmission.Advances in pharmacology (San Diego, Calif.) · 2022
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiao-Fei WangMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.ORCID 0000-0001-7901-5034
Elisabeth BarbierDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201.
Yi-Ting ChiuDepartment of Pharmacology, School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, and.ORCID 0000-0001-7257-7755
Yi HeMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224.
Jia ZhanMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224.
Guo-Hua BiMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224.
Hai-Ying ZhangMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224.ORCID 0000-0003-0593-5940
Bo FengDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201.
Lee-Yuan Liu-ChenDepartment of Pharmacology, School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, and.
Jia Bei WangDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, zxi@mail.nih.gov jwang@rx.umaryland.edu.
Zheng-Xiong XiMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224, zxi@mail.nih.gov jwang@rx.umaryland.edu.ORCID 0000-0001-6482-8104
Target (United States) · USUniversity of Maryland, Baltimore · USTemple University · US

Funding

Pilot Projects Core (PPC)P30DA013429 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI Anjali M Rajadhyaksha · 2000 to 2026
$34.6M
MOR Phosphorylation in Opioid Tolerance and DependenceR01DA011925 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, JIA BEI · 2004 to 2008
$1.5M
MOR PHosphorylation in Opiod Tolerance and DependenceK02DA018722 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, JIA BEI · 2005 to 2009
$609k
MU OPIOID RECEPTOR--PHOSPHORYLATION AND DESENSITIZATIONR29DA011925 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, JIA BEI · 1998 to 2002
$312k
NIDA NIH HHS K02 DA018722NIDA NIH HHS P30 DA013429NIDA NIH HHS R01 DA011925NIDA NIH HHS R29 DA011925
6 · The paper itself

Abstract

The etiology and pathophysiology underlying opioid tolerance and dependence are still unknown. Because mu opioid receptor (MOR) plays an essential role in opioid action, many vulnerability-related studies have focused on single nucleotide polymorphisms of MOR, particularly on A118G. In this study, we found that a single-point mutation at the MOR T394 phosphorylation site could be another important susceptive factor in the development of opioid tolerance and dependence in mice. T394A mutation, in which a threonine at 394 was replaced by an alanine, did not alter agonist binding to MOR and opioid analgesia, but resulted in loss of etorphine-induced MOR internalization in spinal dorsal horn neurons and opioid analgesic tolerance induced by either morphine or etorphine. In addition, this mutation also caused an increase in intravenous heroin self-administration and in nucleus accumbens dopamine response to heroin. These findings suggest that T394 phosphorylation following MOR activation causes MOR internalization and desensitization, which subsequently contributes to the development of tolerance in both opioid analgesia and opioid reward. Accordingly, T394A mutation blocks opioid tolerance and leads to an increase in brain dopamine response to opioids and in opioid-taking behavior. Thus, the T394 may serve as a new drug target for modulating opioid tolerance and the development of opioid abuse and addiction. SIGNIFICANCE STATEMENT: The mechanisms underlying opioid tolerance and susceptibility to opioid addiction remain unclear. The present studies demonstrate that a single-point mutation at the T394 phosphorylation site in the C-terminal of mu opioid receptor (MOR) results in loss of opioid tolerance and enhanced vulnerability to heroin self-administration. These findings suggest that modulation of the MOR-T394 phosphorylation or dephosphorylation status may have therapeutic potential in management of pain, opioid tolerance, and opioid abuse and addiction. Accordingly, MOR-T394 mutation or polymorphisms could be a risk factor in developing opioid abuse and addiction and therefore be used as a new biomarker in prediction and prevention of opioid abuse and addiction.

Indexed as

AnalgesiaAnalgesics, OpioidAnimalsDrug ToleranceEnkephalin, Ala(2)-MePhe(4)-Gly(5)-EtorphineHeroin DependenceMaleMiceMice, Inbred C57BLMorphineMotor ActivityMutationPain MeasurementPhosphorylationPoint MutationAnalgesics, OpioidEnkephalin, Ala(2)-MePhe(4)-Gly(5)-EtorphineMorphineOprm protein, mouseReceptors, Opioid, muaddictionheroinmutationself-administrationT394Aμ opioid receptor

Identifiers

PMID27707973
PMCPMC5050331
OpenAlexW2528707058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.